MedTech West lunchseminar about Alpha Therapy Solutions’ work towards better treatments for disseminated cancer

3
feb
Kammaren, Vita stråket 12, Sahlgrenska University Hospital
11:30-13:00 (incl. a light lunch)

In 2018, 9.5 million people around the world died of cancer. One of the biggest challenges in today’s cancer treatment and diagnostics is the occurrence of metastatic tumors; when the cancer has spread and formed new tumors. Today, chemotherapy is the most widely used treatment method for such disseminated cancer. Chemotherapy affects not only the cancer cells, but also the patient’s healthy cells and therefore the patient’s general condition. In many cases, chemotherapy can not cure patients with disseminated cancer.

Targeted Alpha Therapy with alpha particle emitting drugs is a very promising alternative treatment method for disseminated cancer. The method allows for the targeted and internal irradiation of small cancer tumors. It kills cancer cells with minimal damage to the patient’s healthy cells.

Astatine is the most promising radioactive element for curative Targeted Alpha Therapy. Despite the huge potential, there are no astatinated drugs on the market today. One of the main reasons is the difficulty to scale up clinical trials of potential drug candidates, as these can only be produced manually. A manual manufacturing process does not meet the requirements for major clinical trials, nor for the future production of drugs for regular patient treatments.

The Gothenburg-based company Alpha Therapy Solutions AB has developed and patented a fully automated production module that can produce astatinised drugs in a standardised, reproducible and safe way. The technology will initially be used by research groups around the world for pre-clinical and clinical studies. Their technology will enable more and larger clinical trials in this area, which is directly related to the possibility of developing both effective and gentle patient treatments with astatinised drugs. The technology is also a prerequisite for future routine clinical treatments.

This Gothenburg-based start-up company recently received a Chalmers Ventures Award. At this MedTech West lunch seminar, Milton Lönnroth, Co-Founder & CEO, and Emma Aneheim, Co-Founder & together with Sture Lindegren from the Department of Radiation Physics also one of the inventors behind the technology, will present their groundbreaking technology to us.

We will serve a light lunch to registered participants. Sign up at the latest on Thursday 30 January at 12:00. Welcome!

Register here